IL2 and neoplasm: Additionally, activation of co-stimulatory molecules (CD80, CD86, CD137), exogenous cytokine administration (interleukin-2, interferon-γ), and blockade of tumor angiogenesis can inhibit melanoma progression when combined with GM-CSF–expressing vaccines [32-36].